Targeting of canonical WNT signaling ameliorates experimental sclerodermatous chronic graft-versus-host disease.
暂无分享,去创建一个
S. Krauss | A. Mackensen | S. Karrer | G. Schett | M. Ziemer | A. Beilhack | B. Spriewald | J. Distler | Chih-Wei Chen | Yun Zhang | C. Dees | D. Wolff | J. Winkler | W. Herr | Honglin Zhu | A. Matei | T. Trinh-Minh | Xianyi Meng | Lichong Shen | M. Ditschkowski | K. Dreissigacker | Cuong Tran-Manh | C. Tran-Manh
[1] S. Hanash,et al. Dickkopf-related protein 3 is a novel biomarker for chronic GVHD after allogeneic hematopoietic cell transplantation. , 2020, Blood advances.
[2] J. Distler,et al. Therapeutic molecular targets of SSc-ILD , 2020, Journal of scleroderma and related disorders.
[3] H. Kouji,et al. β-catenin signaling inhibitors ICG-001 and C-82 improve fibrosis in preclinical models of endometriosis , 2019, Scientific Reports.
[4] R. Zeiser. Advances in understanding the pathogenesis of graft‐versus‐host disease , 2019, British journal of haematology.
[5] M. Whitfield,et al. Shared and distinct mechanisms of fibrosis , 2019, Nature Reviews Rheumatology.
[6] W. Birchmeier,et al. The tyrosine phosphatase SHP2 controls TGFβ-induced STAT3 signaling to regulate fibroblast activation and fibrosis , 2018, Nature Communications.
[7] J. Distler,et al. Targeting TGF-β signaling for the treatment of fibrosis. , 2018, Matrix biology : journal of the International Society for Matrix Biology.
[8] B. Blazar,et al. Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets. , 2017, The New England journal of medicine.
[9] Tetsuya Hayashi,et al. R-Spondin1 expands Paneth cells and prevents dysbiosis induced by graft-versus-host disease , 2017, The Journal of experimental medicine.
[10] Julio C. Mantero,et al. Inhibition of β-Catenin Signaling in the Skin Rescues Cutaneous Adipogenesis in Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial of C-82. , 2017, The Journal of investigative dermatology.
[11] K. Loeb,et al. Pilot study of lithium to restore intestinal barrier function in severe graft-versus-host disease , 2017, PloS one.
[12] J. Harty,et al. Differential Requirements for Tcf1 Long Isoforms in CD8+ and CD4+ T Cell Responses to Acute Viral Infection , 2017, The Journal of Immunology.
[13] C. Nicco,et al. Improvement of Sclerodermatous Graft-Versus-Host Disease in Mice by Niclosamide. , 2016, The Journal of investigative dermatology.
[14] M. Dugo,et al. Circulating miRNA panel for prediction of acute graft-versus-host disease in lymphoma patients undergoing matched unrelated hematopoietic stem cell transplantation. , 2016, Experimental hematology.
[15] Chen Zeng,et al. Tcf1 and Lef1 transcription factors establish CD8+ T cell identity through intrinsic HDAC activity , 2016, Nature Immunology.
[16] S. Calatayud,et al. The activation of Wnt signaling by a STAT6-dependent macrophage phenotype promotes mucosal repair in murine IBD , 2015, Mucosal Immunology.
[17] J. Byrd,et al. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. , 2014, The Journal of clinical investigation.
[18] Michael Kahn,et al. Can we safely target the WNT pathway? , 2014, Nature Reviews Drug Discovery.
[19] Farrah C. Steinke,et al. From inception to output, Tcf1 and Lef1 safeguard development of T cells and innate immune cells , 2014, Immunologic Research.
[20] J. Distler,et al. Canonical Wnt signalling as a key regulator of fibrogenesis – implications for targeted therapies? , 2013, Experimental dermatology.
[21] Cord Naujokat,et al. Salinomycin as a Drug for Targeting Human Cancer Stem Cells , 2012, Journal of biomedicine & biotechnology.
[22] F. Egberts,et al. Combined inhibition of c-Abl and PDGF receptors for prevention and treatment of murine sclerodermatous chronic graft-versus-host disease. , 2012, The American journal of pathology.
[23] F. Egberts,et al. Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease. , 2012, Blood.
[24] Tanvir R. Faisal,et al. Experimental determination of Philodendron melinonii and Arabidopsis thaliana tissue microstructure and geometric modeling via finite-edge centroidal Voronoi tessellation. , 2012, Physical review. E, Statistical, nonlinear, and soft matter physics.
[25] R. Atit,et al. Wnt/β-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells. , 2012, Arthritis and rheumatism.
[26] Zuoming Sun,et al. β-Catenin/TCF-1 Pathway in T Cell Development and Differentiation , 2012, Journal of Neuroimmune Pharmacology.
[27] T. Roskams,et al. Macrophage-derived Wnt opposes Notch signaling to specify hepatic progenitor cell fate in chronic liver disease , 2012, Nature Medicine.
[28] Feng Xiao,et al. Single- and two-phase flow in microfluidic porous media analogs based on Voronoi tessellation. , 2012, Lab on a chip.
[29] Oliver Distler,et al. Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis , 2012, Nature Communications.
[30] O. MacDougald,et al. Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: a novel mouse model for scleroderma? , 2011, Arthritis and rheumatism.
[31] C. Colato,et al. Epithelial cells undergoing epithelial mesenchymal transition (EMT) in systemic sclerosis lack caveolin-1 and modulate WNT signaling in the dermis by secreting SFRP4 , 2011 .
[32] K. Akashi,et al. The Wnt agonist R-spondin1 regulates systemic graft-versus-host disease by protecting intestinal stem cells , 2011, The Journal of experimental medicine.
[33] Wei He,et al. Exogenously administered secreted frizzled related protein 2 (Sfrp2) reduces fibrosis and improves cardiac function in a rat model of myocardial infarction , 2010, Proceedings of the National Academy of Sciences.
[34] Alexandre Cloutier,et al. A muscle resident cell population promotes fibrosis in hindlimb skeletal muscles of mdx mice through the Wnt canonical pathway. , 2010, American journal of physiology. Cell physiology.
[35] Bruce J. Melancon,et al. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α. , 2010, Nature chemical biology.
[36] C. Nguyên,et al. Inhibition of Wnt/β-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis , 2010, Proceedings of the National Academy of Sciences.
[37] S. Galande,et al. Global Regulator SATB1 Recruits β-Catenin and Regulates TH2 Differentiation in Wnt-Dependent Manner , 2010, PLoS biology.
[38] Marc W. Kirschner,et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling , 2009, Nature.
[39] R. Nusse,et al. Towards an integrated view of Wnt signaling in development , 2009, Development.
[40] M. Waterman,et al. T cell factor 1 initiates the T helper type 2 fate by inducing the transcription factor GATA-3 and repressing interferon-γ , 2009, Nature Immunology.
[41] Eric S. Lander,et al. Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening , 2009, Cell.
[42] Xi He,et al. Wnt/beta-catenin signaling: components, mechanisms, and diseases. , 2009, Developmental cell.
[43] Youhua Liu,et al. Wnt/beta-catenin signaling promotes renal interstitial fibrosis. , 2009, Journal of the American Society of Nephrology : JASN.
[44] J. Zwerina,et al. The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. , 2009, Arthritis & Rheumatism.
[45] S. Michalek,et al. Glycogen synthase kinase-3beta (GSK3beta) inhibition suppresses the inflammatory response to Francisella infection and protects against tularemia in mice. , 2009, Molecular immunology.
[46] J. Shaughnessy,et al. The role of Dickkopf-1 in bone development, homeostasis, and disease. , 2009, Blood.
[47] W. Seeger,et al. Functional Wnt Signaling Is Increased in Idiopathic Pulmonary Fibrosis , 2008, PloS one.
[48] Xi He,et al. Wnt/beta-catenin signaling: new (and old) players and new insights. , 2008, Current opinion in cell biology.
[49] Xi He,et al. SnapShot: Wnt/β-Catenin Signaling , 2007, Cell.
[50] K. Scott Baker,et al. The management and outcome of chronic graft‐versus‐host disease , 2007, British journal of haematology.
[51] W. Shlomchik,et al. Graft-versus-host disease , 2007, Nature Reviews Immunology.
[52] H. Yagita,et al. Costimulatory molecule-targeted immunotherapy of cutaneous graft-versus-host disease. , 2006, Blood.
[53] T. Krummel,et al. Wnt-4 Expression Is Increased in Fibroblasts after TGF-&bgr;1 Stimulation and during Fetal and Postnatal Wound Repair , 2006, Plastic and reconstructive surgery.
[54] R. Nusse,et al. The Wnt signaling pathway in development and disease. , 2004, Annual review of cell and developmental biology.
[55] R. Storb,et al. Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review , 2004, Springer Seminars in Immunopathology.
[56] V. Poletti,et al. Aberrant Wnt/ (cid:1) -Catenin Pathway Activation in Idiopathic Pulmonary Fibrosis , 2003 .
[57] K. Surendran,et al. A role for Wnt-4 in renal fibrosis. , 2002, American journal of physiology. Renal physiology.
[58] R Grosschedl,et al. Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism. , 2000, Immunity.
[59] Y. DeClerck,et al. Clonal analysis of murine graft-vs-host disease. II. Leukokines that stimulate fibroblast proliferation and collagen synthesis in graft-vs. host disease. , 1986, Journal of immunology.
[60] B. Jaffee,et al. Chronic graft-versus-host disease (GVHD) as a model for scleroderma. I. Description of model systems. , 1983, Cellular immunology.
[61] B. N. Das,et al. Clinical trial of piperazine hydrate and pyrvinium pamoate in ascariasis and oxyuriasis infestation , 1979, Indian journal of pediatrics.
[62] E. Holler,et al. Graft-versus-host disease , 2009, The Lancet.
[63] F. Riechers. [On the diagnosis and therapy of oxyuriasis]. , 1967, Zeitschrift fur arztliche Fortbildung.
[64] A. Desai. Single-dose Treatment of Oxyuriasis with Pyrvinium Embonate , 1962, British medical journal.
[65] M. Mohty,et al. Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[66] J. Ritz,et al. Current challenges in chronic graft-versus-host disease. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[67] W. Rom,et al. Wnt pathway in pulmonary fibrosis in the bleomycin mouse model. , 2009, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.
[68] R. Nusse,et al. Wnt signaling in disease and in development , 2005, Cell Research.
[69] H. Clevers,et al. WNT signalling and haematopoiesis: a WNT–WNT situation , 2005, Nature Reviews Immunology.